



Novel Therapeutic Targets and Drug Development in Retinal Diseases

Guest Editor:

Dr. Blanca Arango-Gonzalez

Institute for Ophthalmic
Research, Department for
Ophthalmology, Eberhard Karls
University of Tübingen, 72076
Tübingen, Germany

Deadline for manuscript
submissions:

closed (10 June 2023)

Message from the Guest Editor

Dear Colleagues,

Many ocular diseases caused by endogenous or exogenous insults lead to photoreceptor cell death, the ultimate cause of vision loss in various retinal diseases, which are currently not properly treated despite the increasing prevalence. The light-sensitive photoreceptor cells are terminally differentiated neurons that are not regenerated after degeneration or injury in adult mammals. The high heterogeneity of factors inducing photoreceptor degeneration hampers the development of effective therapeutic interventions. Several cellular and biochemical processes can contribute to photoreceptor death, including endoplasmic reticulum stress and unfolded protein response, oxidative stress, and inflammation, offering a vast repertoire of potential therapeutic targets.

This Special Issue entitled “Novel Therapeutic Targets and Drug Development in Retinal Diseases” will contribute to understanding disease mechanisms better, opening novel avenues for targeting photoreceptor degeneration and accelerating the development and characterization of compounds for preclinical studies as a starting point for advanced drug development.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
[@MDPIpharma](https://twitter.com/MDPIpharma)